secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2026-08-06T20:34:51+00:00
Accession:  0001193125-26-338273
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica Q2 net loss $13.2M; YCANTH dispensed units up 28% sequentially, 46% YoY
-------------------------------------------------------------------------------

- Q2 total revenue $5.9M (down from $12.7M YoY due to $8M milestone in prior year); YCANTH net product revenue $5.1M (+18.7% QoQ, +12.3% YoY).
- Q2 net loss $13.2M ($0.62/share) vs net income $0.2M in Q2 2025; non-GAAP net loss $10.2M ($0.48/share).
- YCANTH dispensed applicator units reached 19,626 in Q2, up 28.3% QoQ and 46.1% YoY; record quarterly demand.
- Entered $27.5M credit facility with Chairman Paul B. Manning; cash runway could extend into 2028.
- Phase 3 common warts topline data expected mid-2027; COVE-2 and COVE-3 trials recruiting; settled 2022 class action for $1.7M after insurance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312526338273/0001193125-26-338273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312526338273/d13828d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-338273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer